BIOMARKER FOR PREDICTING RESPONSIVENESS TO ANTICANCER AGENT AND USE THEREOF

The present invention relates to a biomarker for predicting responsiveness to an anticancer agent and a use thereof, and more particularly, to: a marker composition for predicting responsiveness to atezolizumab, avelumab, or durvalumab, the marker composition comprising at least one gene selected fr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	LEE, Jee Yun, KIM, Kyoung Mee
Format:	Patent
Sprache:	eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PHYSICS PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to a biomarker for predicting responsiveness to an anticancer agent and a use thereof, and more particularly, to: a marker composition for predicting responsiveness to atezolizumab, avelumab, or durvalumab, the marker composition comprising at least one gene selected from the group consisting of armadillo repeat-containing X-linked protein 1 (ARMCX1), serine/threonine-protein kinase D1 (PRKD1), and tyrosine kinase 2 (TYK2), or protein(s) encoded by the at least one gene; a composition for predicting responsiveness; a kit comprising the composition; and a method for providing information for predicting responsiveness. Gene markers according to the present invention are analyzed using patient-derived formalin-fixed paraffin-embedded tissues, and thus do not require the separate collection of samples, and the therefore convenient to analyze.